Silo Pharma Inc. (NASDAQ: SILO) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering SPC-15, its lead intranasal therapeutic targeting post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes composition and method claims related to the company's proprietary therapeutic approach to preventing or delaying stress-induced behavioral responses. A corresponding patent was issued by the Japan Patent Office earlier this year.
A Notice of Allowance indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly. Silo said the U.S. patent protection is an important component of its strategy as it advances SPC-15 development for PTSD, adding to its biopharmaceutical intellectual property portfolio of issued and allowed patents. To view the full press release, visit https://ibn.fm/Hh4Z6.
This development matters because PTSD is a debilitating condition that affects millions worldwide, and current treatment options are often limited. SPC-15 represents a novel approach that could prevent or reduce stress-induced fear, depressive-like and anxiety-like behaviors. By securing patent protection in the U.S., Silo Pharma strengthens its ability to commercialize SPC-15 and attract potential partners or investors. The patent allowance also validates the company's innovative research and may accelerate its path to clinical trials, bringing hope to patients who have not responded to existing therapies.
Beyond PTSD, Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. For more information, visit silopharma.com.
The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO. This announcement underscores Silo Pharma's commitment to advancing novel therapies for unmet medical needs and could have a positive impact on its stock and future prospects. For the biopharmaceutical industry, it highlights the importance of intellectual property in driving innovation and investment in mental health treatments. For patients and healthcare providers, it signals progress toward new options for managing PTSD and related disorders.
